Neurology Medical News about multiple sclerosis, dendritic cells, regulatory T-cells, interferon-beta-1a, responders

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Clinical response to interferon-β-1a may be linked to low baseline circulating BDCA1 myeloid dendritic cells: Differential role of circulating dendritic cells and CD4+ regulatory T-cells in relapsing-remitting multiple sclerosis: A 1-year longitudinal study
Journal of Neuroimmunology, 07/27/09

de Andrés C et al. – A real-life observational 1-yr longitudinal study of 23 relapsing–remitting multiple sclerosis (RRMS) pts treated with subcutaneous interferon-β-1a (IFN-β-1a) shows a lower proportion of circulating myeloid dendritic cells (mDCs) than in healthy controls at baseline.

Methods

Both univariate (Kaplan–Meier) and multivariate (Cox regression) analyses to determine which variables were associated with clinical response to IFN-β-1a
Variables: age, sex, baseline EDSS, MS relapse rates 1 yr and 2 yrs before initiating IFN-β-1a, mDCs and plasmacytoid (pDCs) subsets, activated and regulatory CD4+ T-cells (TReg)

Results

During 1 yr of treatment, shift towards lower proportions of CD123+ pDCs expression and higher numbers and function of TReg
On univariate analysis, MS activity significantly associated with baseline BDCA1+ mDCs ≤0.4%
On Cox model analysis, baseline BDCA1+ mDCs was the most closely associated factor with MS activity on IFN treatment during 1-yr follow-up

<< Previous
Risk factors associated with injury attributable to falling among...

Next >>
Incidence and Predictors of Stroke Associated With Percutaneous...